Personal information

myology, muscular dystrophy, exon skipping
Japan

Activities

Employment (1)

National Center of Neurology and Psychiatry: Tokyo, JP

Director general emeritus
Employment
Source: Self-asserted source
Shin'ichi Takeda

Education and qualifications (1)

National Center of Neurology and Psychiatry: Tokyo, JP

Qualification
Source: Self-asserted source
Shin'ichi Takeda

Works (50 of 56)

Items per page:
Page 1 of 2

Brain Dp140 alters glutamatergic transmission and social behaviour in the mdx52 mouse model of Duchenne muscular dystrophy.

Progress in neurobiology
2022-05 | Journal article
Contributors: Hashimoto Y; Kuniishi H; Sakai K; Fukushima Y; Du X; Yamashiro K; Hori K; Imamura M; Hoshino M; Yamada M et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Duchenne muscular dystrophy diagnosis using fibroblast-derived myotube cells.

Pediatrics international : official journal of the Japan Pediatric Society
2022-01 | Journal article
Contributors: Okada Y; Funato M; Takeda S; Kaneko H
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Development of outcome measures according to dystrophic phenotypes in canine X-linked muscular dystrophy in Japan.

Experimental animals
2021-06 | Journal article
Contributors: Kuraoka M; Aoki Y; Takeda S
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Duchenne muscular dystrophy.

Nature reviews. Disease primers
2021-02 | Journal article
Contributors: Duan D; Goemans N; Takeda S; Mercuri E; Aartsma-Rus A
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Enhanced cell survival and therapeutic benefits of IL-10-expressing multipotent mesenchymal stromal cells for muscular dystrophy.

Stem cell research & therapy
2021-02 | Journal article
Contributors: Nitahara-Kasahara Y; Kuraoka M; Oda Y; Hayashita-Kinoh H; Takeda S; Okada T
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Dental pulp stem cells can improve muscle dysfunction in animal models of Duchenne muscular dystrophy.

Stem cell research & therapy
2021-01 | Journal article
Contributors: Nitahara-Kasahara Y; Kuraoka M; Guillermo PH; Hayashita-Kinoh H; Maruoka Y; Nakamura-Takahasi A; Kimura K; Takeda S; Okada T
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Exon-Skipping in Duchenne Muscular Dystrophy.

Journal of neuromuscular diseases
2021-01 | Journal article
Contributors: Takeda S; Clemens PR; Hoffman EP
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Improved transduction of canine X-linked muscular dystrophy with rAAV9-microdystrophin via multipotent MSC pretreatment.

Molecular therapy. Methods & clinical development
2020-11 | Journal article
Contributors: Hayashita-Kinoh H; Guillermo PH; Nitahara-Kasahara Y; Kuraoka M; Okada H; Chiyo T; Takeda S; Okada T
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

The nSMase2/Smpd3 gene modulates the severity of muscular dystrophy and the emotional stress response in mdx mice.

BMC medicine
2020-11 | Journal article
Contributors: Matsuzaka Y; Tanihata J; Ooshima Y; Yamada D; Sekiguchi M; Miyatake S; Aoki Y; Terumitsu M; Yashiro R; Komaki H et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Mutation-independent Proteomic Signatures of Pathological Progression in Murine Models of Duchenne Muscular Dystrophy.

Molecular & cellular proteomics : MCP
2020-09 | Journal article
Contributors: van Westering TLE; Johansson HJ; Hanson B; Coenen-Stass AML; Lomonosova Y; Tanihata J; Motohashi N; Yokota T; Takeda S; Lehtiö J et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Publisher Correction: Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride.

Scientific reports
2020-02 | Journal article
Contributors: Takizawa H; Hara Y; Mizobe Y; Ohno T; Suzuki S; Inoue K; Takeshita E; Shimizu-Motohashi Y; Ishiyama A; Hoshino M et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Clinical practice with steroid therapy for Duchenne muscular dystrophy: An expert survey in Asia and Oceania.

Brain & development
2020-01 | Journal article
Contributors: Takeuchi F; Nakamura H; Yonemoto N; Komaki H; Rosales RL; Kornberg AJ; Bretag AH; Dejthevaporn C; Goh KJ; Jong YJ et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Early phase 2 trial of TAS-205 in patients with Duchenne muscular dystrophy.

Annals of clinical and translational neurology
2020-01 | Journal article
Contributors: Komaki H; Maegaki Y; Matsumura T; Shiraishi K; Awano H; Nakamura A; Kinoshita S; Ogata K; Ishigaki K; Saitoh S et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Expectations and anxieties of Duchenne muscular dystrophy patients and their families during the first-in-human clinical trial of NS-065/NCNP-01.

Brain & development
2020-01 | Journal article
Contributors: Shimizu R; Ohata M; Tachimori H; Kimura E; Harada Y; Takeshita E; Tamaura A; Takeda S; Komaki H
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Amelioration of intracellular Ca2+ regulation by exon-45 skipping in Duchenne muscular dystrophy-induced pluripotent stem cell-derived cardiomyocytes.

Biochemical and biophysical research communications
2019-10 | Journal article
Contributors: Sato M; Shiba N; Miyazaki D; Shiba Y; Echigoya Y; Yokota T; Takizawa H; Aoki Y; Takeda S; Nakamura A
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Psychiatric and neurodevelopmental aspects of Becker muscular dystrophy.

Neuromuscular disorders : NMD
2019-09 | Journal article
Contributors: Mori-Yoshimura M; Mizuno Y; Yoshida S; Ishihara N; Minami N; Morimoto E; Maruo K; Nonaka I; Komaki H; Nishino I et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases.

EBioMedicine
2019-06 | Journal article
Contributors: Tsoumpra MK; Fukumoto S; Matsumoto T; Takeda S; Wood MJA; Aoki Y
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride.

Scientific reports
2019-03 | Journal article
Contributors: Takizawa H; Hara Y; Mizobe Y; Ohno T; Suzuki S; Inoue K; Takeshita E; Shimizu-Motohashi Y; Ishiyama A; Hoshino M et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Characterization of a novel microRNA, miR-188, elevated in serum of muscular dystrophy dog model.

PloS one
2019-01 | Journal article
Contributors: Shibasaki H; Imamura M; Arima S; Tanihata J; Kuraoka M; Matsuzaka Y; Uchiumi F; Tanuma SI; Takeda S
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches.

Journal of personalized medicine
2019-01 | Journal article
Contributors: Shimizu-Motohashi Y; Komaki H; Motohashi N; Takeda S; Yokota T; Aoki Y
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Efficacy of Prednisolone in Generated Myotubes Derived From Fibroblasts of Duchenne Muscular Dystrophy Patients.

Frontiers in pharmacology
2018-12 | Journal article
Contributors: Kameyama T; Ohuchi K; Funato M; Ando S; Inagaki S; Sato A; Seki J; Kawase C; Tsuruma K; Nishino I et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

A phase I study of TAS-205 in patients with Duchenne muscular dystrophy.

Annals of clinical and translational neurology
2018-10 | Journal article
Contributors: Takeshita E; Komaki H; Shimizu-Motohashi Y; Ishiyama A; Sasaki M; Takeda S
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.

Molecular therapy : the journal of the American Society of Gene Therapy
2018-10 | Journal article
Contributors: Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy.

Molecular therapy. Nucleic acids
2018-09 | Journal article
Contributors: Watanabe N; Nagata T; Satou Y; Masuda S; Saito T; Kitagawa H; Komaki H; Takagaki K; Takeda S
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.

Science translational medicine
2018-04 | Journal article
Contributors: Komaki H; Nagata T; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Characteristics of Japanese Patients with Becker Muscular Dystrophy and Intermediate Muscular Dystrophy in a Japanese National Registry of Muscular Dystrophy (Remudy): Heterogeneity and Clinical Variation.

Journal of neuromuscular diseases
2018-01 | Journal article
Contributors: Mori-Yoshimura M; Mitsuhashi S; Nakamura H; Komaki H; Goto K; Yonemoto N; Takeuchi F; Hayashi YK; Murata M; Takahashi Y et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.

Methods in molecular biology (Clifton, N.J.)
2018-01 | Journal article
Contributors: Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Exon Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy.

Methods in molecular biology (Clifton, N.J.)
2018-01 | Journal article
Contributors: Hara Y; Mizobe Y; Miyatake S; Takizawa H; Nagata T; Yokota T; Takeda S; Aoki Y
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Social involvement issues in patients with Becker muscular dystrophy: A questionnaire survey of subjects from a patient registry.

Brain & development
2017-11 | Journal article
Contributors: Mori-Yoshimura M; Mizuno Y; Yoshida S; Minami N; Yonemoto N; Takeuchi F; Nishino I; Murata M; Takeda S; Takahashi Y et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice.

Skeletal muscle
2017-10 | Journal article
Contributors: Wada E; Tanihata J; Iwamura A; Takeda S; Hayashi YK; Matsuda R
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

A comparative study of care practices for young boys with Duchenne muscular dystrophy between Japan and European countries: Implications of early diagnosis.

Neuromuscular disorders : NMD
2017-07 | Journal article
Contributors: Takeuchi F; Komaki H; Yamagata Z; Maruo K; Rodger S; Kirschner J; Kubota T; Kimura E; Takeda S; Gramsch K et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy
2017-07 | Journal article
Contributors: Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.

Proceedings of the National Academy of Sciences of the United States of America
2017-04 | Journal article
Contributors: Echigoya Y; Nakamura A; Nagata T; Urasawa N; Lim KRQ; Trieu N; Panesar D; Kuraoka M; Moulton HM; Saito T et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Induction of Pluripotent Stem Cells from a Manifesting Carrier of Duchenne Muscular Dystrophy and Characterization of Their X-Inactivation Status.

Stem cells international
2017-04 | Journal article
Contributors: Miyagoe-Suzuki Y; Nishiyama T; Nakamura M; Narita A; Takemura F; Masuda S; Minami N; Murayama K; Komaki H; Goto YI et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.

Methods in molecular biology (Clifton, N.J.)
2017-01 | Journal article
Contributors: Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy.

Cell death and differentiation
2016-11 | Journal article
Contributors: Vila MC; Rayavarapu S; Hogarth MW; Van der Meulen JH; Horn A; Defour A; Takeda S; Brown KJ; Hathout Y; Nagaraju K et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Inflammatory predisposition predicts disease phenotypes in muscular dystrophy.

Inflammation and regeneration
2016-09 | Journal article
Contributors: Nitahara-Kasahara Y; Takeda S; Okada T
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors.

Drug design, development and therapy
2016-08 | Journal article
Contributors: Miyatake S; Shimizu-Motohashi Y; Takeda S; Aoki Y
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network.

BMC health services research
2016-07 | Journal article
Contributors: Shimizu R; Ogata K; Tamaura A; Kimura E; Ohata M; Takeshita E; Nakamura H; Takeda S; Komaki H
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Trends in steroid therapy for Duchenne muscular dystrophy in Japan.

Muscle & nerve
2016-07 | Journal article
Contributors: Takeuchi F; Komaki H; Nakamura H; Yonemoto N; Kashiwabara K; Kimura E; Takeda S
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials.

American journal of translational research
2016-06 | Journal article
Contributors: Shimizu-Motohashi Y; Miyatake S; Komaki H; Takeda S; Aoki Y
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy.

Journal of visualized experiments : JoVE
2016-05 | Journal article
Contributors: Miskew Nichols B; Aoki Y; Kuraoka M; Lee JJ; Takeda S; Yokota T
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Utility of Cystatin C for Estimating Glomerular Filtration Rate in Patients With Muscular Dystrophy.

International heart journal
2016-05 | Journal article
Contributors: Kimura K; Morita H; Daimon M; Horio M; Kawata T; Nakao T; Hirokawa M; Kitao R; Watanabe D; Komori T et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy.

The American journal of pathology
2016-03 | Journal article
Contributors: Kuraoka M; Kimura E; Nagata T; Okada T; Aoki Y; Tachimori H; Yonemoto N; Imamura M; Takeda S
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

[Changes in cytosolic Ca<sup>2+</sup>dynamics associated with muscular dystrophy.]

Clinical calcium
2016-01 | Journal article
Contributors: Tanihata J; Takeda S
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Comparison of Experimental Protocols of Physical Exercise for mdx Mice and Duchenne Muscular Dystrophy Patients.

Journal of neuromuscular diseases
2015-11 | Journal article
Contributors: Hyzewicz J; Ruegg UT; Takeda S
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Mesoangioblast delivery of miniagrin ameliorates murine model of merosin-deficient congenital muscular dystrophy type 1A.

Skeletal muscle
2015-09 | Journal article
Contributors: Domi T; Porrello E; Velardo D; Capotondo A; Biffi A; Tonlorenzi R; Amadio S; Ambrosi A; Miyagoe-Suzuki Y; Takeda S et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Characterization of WWP1 protein expression in skeletal muscle of muscular dystrophy chickens.

Journal of biochemistry
2015-08 | Journal article
Contributors: Imamura M; Nakamura A; Mannen H; Takeda S
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Differential roles of MMP-9 in early and late stages of dystrophic muscles in a mouse model of Duchenne muscular dystrophy.

Biochimica et biophysica acta
2015-07 | Journal article
Contributors: Shiba N; Miyazaki D; Yoshizawa T; Fukushima K; Shiba Y; Inaba Y; Imamura M; Takeda S; Koike K; Nakamura A
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central

Erratum: G-CSF supports long-term muscle regeneration in mouse models of muscular dystrophy.

Nature communications
2015-06 | Journal article
Contributors: Hayashiji N; Yuasa S; Miyagoe-Suzuki Y; Hara M; Ito N; Hashimoto H; Kusumoto D; Seki T; Tohyama S; Kodaira M et al.
Source: Self-asserted source
Shin'ichi Takeda via Europe PubMed Central
Items per page:
Page 1 of 2

Peer review (3 reviews for 3 publications/grants)

Review activity for Nature communications (1)
Review activity for npj regenerative medicine. (1)
Review activity for Skeletal muscle. (1)